Terran Biosciences announces publication of PCT patent application covering novel non-hallucinogenic psychoplastogens, including derivatives of DMT and ibogaine with improved pharmacokinetics and engagement at target receptors

NEW YORK, May 5, 2023 /PRNewswire/ — Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of two PCT patent applications covering novel psychoplastogens, including non-hallucinogenic derivatives of DMT and ibogaine. DMT and ibogaine are both potent psychedelic…

Source